当前位置:易推广 > 上海陶术生物科技有限公司 > 产品展示
企业档案
会员类型:会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累,可浏览访问
(41-90)良好信誉积累,可接洽商谈
(91+ )优质信誉积累,可持续信赖
易推广会员:5年
最后认证时间:
注册号: 【已认证】
法人代表: 【已认证】
企业类型:生产商 【已认证】
注册资金:人民币万 【已认证】
产品数:86101
参观次数:3887266
已选条件
-
T9935UCM-1336UCM 1336,UCM1336
UCM-1336 is a potent ICMT inhibitor with an IC50 of 2 μM which is selective against the other enzymes involved in the post-translational modifications of Ras.
价 格:¥电议型 号:T9935产 地:中国大陆
-
T19935XD14
XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
价 格:¥电议型 号:T19935产 地:中国大陆
-
T79935Forrestiacids J;化合物 Forrestiacids JForrestiacids J
Forrestiacid J is an inhibitor of ATP-citrate lyase (ACL), exhibiting an IC50 value of 2.6 μM [1].
价 格:¥电议型 号:T79935产 地:中国大陆
-
T71041Org 9935;化合物 Org 9935Org 9935
Org 9935 is a potent, selective PDE3 inhibitor with IC50 of 50 nM.
价 格:¥电议型 号:T71041产 地:中国大陆
-
T69935L0909;化合物 L0909L0909
L0909 is an orally available inhibitors of Hepatitis C virus with a novel mechanism of action (EC50 = 0.022 μM, SI > 600). L0909 could block HCV replication by acting on the HCV entry stage. The high sensitivity to clinical resistant HCV mutants and synergistic effect with clinical drugs were observed for this compound. L0909 as a promising HCV entry inhibitor for single or combinational therapeutic potential.
价 格:¥电议型 号:T69935产 地:中国大陆
-
T39935TRPA1-IN-1TRPA1-IN-1TRPA1-IN-1
TRPA1-IN-1 is a potent, selective antagonist of the TRPA1 channel, demonstrating significant oral bioavailability as a small molecule.
价 格:¥电议型 号:T39935产 地:中国大陆
-
T19935XD14;化合物XD14XD14
XD14 is an inhibitor of BET bromodomain (Kd of 160 nM, 170 nM, 380 nM, 490 nM, 830 nM and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2), respectively).
价 格:¥电议型 号:T19935产 地:中国大陆